NCT01946516

Brief Summary

The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,051

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2013

Longer than P75 for all trials

Geographic Reach
1 country

58 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 29, 2013

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

September 16, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 19, 2013

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
4.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 13, 2022

Completed
9 months until next milestone

Results Posted

Study results publicly available

July 3, 2023

Completed
Last Updated

July 3, 2023

Status Verified

June 1, 2023

Enrollment Period

4.3 years

First QC Date

September 16, 2013

Results QC Date

April 21, 2023

Last Update Submit

June 13, 2023

Conditions

Keywords

viral screening

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Positive Viral Infection

    An estimate of the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection among newly diagnosed cancer participants presenting to SWOG-affiliated community and academic oncology clinics.

    Up to 21 days after registration

Secondary Outcomes (7)

  • Presence of Important Risk Factors in Participants Tested for Previous HBV

    Up to 21 days after registration

  • Presence of Important Risk Factors in Participants Tested for Chronic HBV

    Up to 21 days after registration

  • Presence of Important Risk Factors in Participants Tested for HCV

    Up to 21 days after registration

  • Presence of Important Risk Factors in Participants Tested for HIV

    Up to 21 days after registration

  • Type of Treatment for Cancer and Virus in Participants With Positive Viral Test

    60 days after registration

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Community and academic oncology clinics

You may qualify if:

  • presenting for evaluation or treatment of a new cancer malignancy(including hematologic)
  • confirmed pathologic diagnosis must be within 120 days of registration (Patients presenting for "second opinions" of confirmed malignancies are eligible, including those who have started cancer treatment at other facilities)
  • at least 18 years of age
  • patient must have had their blood drawn for HIV, HBV and HCV testing prior to registration (Patients who have had HIV, HBV and/or HCV testing within 60 days prior to registration and who do not wish to be retested are eligible, provided supporting documents can be obtained confirming viral test results for all three viruses. Documentation must be obtained prior to registration.
  • Patients who are viral positive for either HIV, HBV, and/or HCV and who do not wish to be retested are eligible, provided documentation of viral load within 120 days prior to registration can be obtained. Note that these patients must be tested for or provide current viral load for all three viruses to be eligible. Documentation must be obtained prior to registration.)
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines
  • Patients must be offered the opportunity to allow their blood specimens to be banked by the SWOG Repository for future research

You may not qualify if:

  • diagnosed with a malignancy other than the current malignancy within the past five years (with the exception of basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ breast cancer.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (58)

Kaiser Permanente Hospital

Fontana, California, 92335, United States

Location

Kaiser Permanente - Harbor City

Harbor City, California, 90710, United States

Location

Contra Costa Regional Medical Center

Martinez, California, 94553-3156, United States

Location

East Bay Physicians Medical Group-Summit

Oakland, California, 94609, United States

Location

Kaiser Permanente-Oakland

Oakland, California, 94611, United States

Location

Desert Regional Medical Center

Palm Springs, California, 92262, United States

Location

Kaiser Permanente - Panorama City

Panorama City, California, 91402, United States

Location

Kaiser Permanente-Roseville

Roseville, California, 95661, United States

Location

Kaiser Permanente-San Francisco

San Francisco, California, 94115, United States

Location

Kaiser Permanente Medical Center-Vacaville

Vacaville, California, 95688, United States

Location

Kaiser Permanente-Lone Tree

Lone Tree, Colorado, 80124, United States

Location

University of Hawaii Cancer Center

Honolulu, Hawaii, 96813, United States

Location

Tripler Army Medical Center

Honolulu, Hawaii, 96859, United States

Location

Saint Luke's Mountain States Tumor Institute - Meridian

Meridian, Idaho, 83642, United States

Location

Mac Neal Hospital

Berwyn, Illinois, 60402, United States

Location

Weiss Memorial Hospital

Chicago, Illinois, 60640, United States

Location

Hines Veterans Administration Hospital

Hines, Illinois, 60141, United States

Location

West Suburban Medical Center

River Forest, Illinois, 60305, United States

Location

Veteran Administration Eastern Kansas Healthcare

Leavenworth, Kansas, 66048, United States

Location

Topeka VA Hospital

Topeka, Kansas, 66622, United States

Location

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805, United States

Location

Louisiana Hematology Oncology Associates LLC

Baton Rouge, Louisiana, 70809, United States

Location

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809, United States

Location

Medical Oncology LLC

Baton Rouge, Louisiana, 70809, United States

Location

Mary Bird Cancer Center/Saint Tammany Parish

Covington, Louisiana, 70433, United States

Location

Women's Cancer Care-Covington

Covington, Louisiana, 70433, United States

Location

Mary Bird Perkins Cancer Center/Terrebonne General Medical Center

Houma, Louisiana, 70360, United States

Location

Oncology Center of The South Incorporated

Houma, Louisiana, 70360, United States

Location

East Jefferson General Hospital

Metairie, Louisiana, 70006, United States

Location

University Health-Conway

Monroe, Louisiana, 71202, United States

Location

University Medical Center New Orleans

New Orleans, Louisiana, 70112, United States

Location

Louisiana State University Health Sciences Center Shreveport

Shreveport, Louisiana, 71103, United States

Location

North Shore Hematology Oncology Associates Inc

Slidell, Louisiana, 70458, United States

Location

Boston Medical Center

Boston, Massachusetts, 02118, United States

Location

Kansas City Veterans Affairs Medical Center

Kansas City, Missouri, 64128, United States

Location

Billings Clinic Cancer Center

Billings, Montana, 59101, United States

Location

Saint James Community Hospital and Cancer Treatment Center

Butte, Montana, 59701, United States

Location

Columbia University/Herbert Irving Cancer Center

New York, New York, 10032, United States

Location

Adena Regional Medical Center

Chillicothe, Ohio, 45601, United States

Location

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214, United States

Location

Grant Medical Center

Columbus, Ohio, 43215, United States

Location

OneHealth Marion General Hospital

Marion, Ohio, 43302, United States

Location

Knox Community Hospital

Mount Vernon, Ohio, 43050, United States

Location

Licking Memorial Hospital

Newark, Ohio, 43055, United States

Location

Southern Ohio Medical Center

Portsmouth, Ohio, 45662, United States

Location

Kaiser Permanente Northwest

Portland, Oregon, 97227, United States

Location

Greenville Health System Cancer Institute-Andrews

Greenville, South Carolina, 29605, United States

Location

Greenville Health System Cancer Institute-Butternut

Greenville, South Carolina, 29605, United States

Location

Greenville Health System Cancer Institute-Faris

Greenville, South Carolina, 29605, United States

Location

Greenville Memorial Hospital

Greenville, South Carolina, 29605, United States

Location

Greenville Health System Cancer Institute-Eastside

Greenville, South Carolina, 29615, United States

Location

Greenville Health System Cancer Institute-Greer

Greer, South Carolina, 29650, United States

Location

Greenville Health System Cancer Institute-Seneca

Seneca, South Carolina, 29672, United States

Location

Greenville Health System Cancer Institute-Spartanburg

Spartanburg, South Carolina, 29307, United States

Location

The Don and Sybil Harrington Cancer Center

Amarillo, Texas, 79106, United States

Location

Lyndon Baines Johnson General Hospital

Houston, Texas, 77026-1967, United States

Location

Audie L Murphy Veterans Affairs Hospital

San Antonio, Texas, 78209, United States

Location

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Specimen submission is optional.

MeSH Terms

Conditions

Neoplasms

Results Point of Contact

Title
Cancer Care Delivery Committee Statistician
Organization
SWOG Statistics and Data Management Center

Study Officials

  • Scott D. Ramsey, M.D.

    Fred Hutchinson Cancer Center

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2013

First Posted

September 19, 2013

Study Start

August 29, 2013

Primary Completion

January 1, 2018

Study Completion

October 13, 2022

Last Updated

July 3, 2023

Results First Posted

July 3, 2023

Record last verified: 2023-06

Locations